LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) continues its investigation on behalf PetMed Express, Inc. (“PETMED” or the “Company”) (NASDAQ: PETS) concerning the Company and its officers’ possible violations of federal securities laws. To obtain information or aid in the investigation, please visit the PETMED investigation page on our website at www.glancylaw.com/case/petmed-express-inc.
On August 23, 2017, Aurelius Value published a report alleging that the Company targets opioid users with Google ads and other marketing techniques to facilitate the abuse of opiates. On this news, shares of PETMED stock dropped $3.19 per share, or over 8% to close at $36.22 per share on August 23, 2017, thereby damaging investors.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased PETMED securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.